Dr. Patrick Nemechek revisits small intestinal bacterial overgrowth (SIBO) and shares a research review perspective: many chronic medical problems are increasingly being linked to inflammatory stress associated with SIBO. In the video, he emphasizes that this is not a niche gastrointestinal issue—it is being discussed in the literature in relation to multiple organ systems and a wide range of diagnoses.
This article summarizes the framework and practical points he discusses, including why the small intestine is vulnerable to immune activation when bacterial overgrowth occurs, why he considers commonly used tests imperfect, and how his clinic approaches lowering inflammation and intestinal permeability as part of a long-term strategy.
What SIBO is (and what “normal” bacterial geography looks like)
In Dr. Nemechek’s explanation, a key concept is that the small intestine and large intestine normally host very different amounts of bacteria. He describes the small intestine as “almost sterile” compared with the colon. In his words, the colon contains vastly more bacteria—on the order of trillions overall—whereas the small intestine is designed to have very few.
SIBO, in this model, occurs when bacteria that typically belong in the colon migrate and overgrow in the small intestine. He uses an analogy (illustrated in the video) of “fish” (colon-type bacteria) living where “birds” (small-intestine-type bacteria) should be. He notes that in SIBO the increase in bacterial load in the small intestine can be enormous—on the order of 10,000 to 100,000 times higher than intended—and that the small intestine is “not built for this.”
Why SIBO may generate large inflammatory responses in his framework
Dr. Nemechek attributes much of the clinical significance of SIBO to what happens at the intestinal barrier and immune interface. He explains that the small-intestinal barrier is extremely thin—about one cell thick—because it ordinarily does not need to hold back large quantities of bacteria or bacterial fragments.
In the framework discussed in the video, excess bacteria in the small intestine can overwhelm that thin barrier, contributing to increased intestinal permeability (“leaky gut”). He emphasizes the immune proximity: he states that approximately 70% of the body’s immune cells (white blood cells capable of generating inflammation) are positioned immediately behind that intestinal lining. When material passes through the barrier—whether bacterial fragments or even food fragments—those immune cells can react, potentially producing “massive amounts of inflammation.”
He also notes that while people often think of white blood cells as being “in the bloodstream,” he describes circulating white blood cells as a small fraction (he cites about 3%), with the rest “parked in the tissue.” In his view, this intestinal immune positioning helps explain why SIBO-related permeability can produce outsized inflammatory consequences.
A review paper’s “12 groups of diseases” linked to SIBO (as presented in the video)
Dr. Nemechek highlights a recent review paper (which he says he links in the video description) that organizes conditions into “12 groups of diseases related to SIBO.” He walks through categories and examples shown on the chart, including:
- Gastrointestinal and hepatobiliary conditions (he references intestinal conditions and fatty liver disease on the chart).
- Cardiometabolic and vascular disease, including heart failure, diabetes, heart disease/atherosclerosis, and he adds that strokes are “probably” included within that grouping.
- Endocrine and organ disease categories that he notes are listed, including thyroid disease and kidney disease.
- Cancers that he says appear on the chart, including pancreatic cancer and gastric and rectal cancers, among others.
- Neuropsychiatric and neurologic conditions, including depression, anxiety, autism (which he notes he has discussed for many years), Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis; he also mentions schizophrenia as an addition.
Importantly, he frames this as an emerging research linkage: “most of everything you hear that people are sick with,” he says, is now being tied back to inflammatory stress from SIBO. His conclusion from that review is straightforward: people should be paying attention to SIBO and working to reverse it.
Why he says common SIBO testing isn’t very good
Dr. Nemechek is critical of commonly used SIBO testing, stating that “the SIBO tests aren’t very good.” Rather than relying on breath testing, he describes a practical, response-based approach: treat for SIBO and watch symptoms.
In his clinical interpretation, two interventions are particularly informative because, as he states, they “only” address SIBO:
- Inulin (a prebiotic fiber)
- Rifaximin (he refers to it as a non-absorbable antibiotic; sold in the U.S. under the brand name Xifaxan)
He suggests that if a person feels better when using inulin and/or rifaximin, that response is more accurate than a breath test in indicating the presence of SIBO—again, presented as his practical clinical stance in the video.
His clinic’s protocol focus: lowering inflammation and intestinal permeability
Dr. Nemechek explains that his clinic’s protocol has been focused on reducing inflammation for about 20 years, with the goal of preventing the development of chronic problems and, in some cases, reversing them. Within that approach, he emphasizes several components:
1) Balance omega fatty acids (his framework)
He describes lowering inflammation by “balancing our omega fatty acids,” using:
- Fish oil, which he describes as providing omega-3s—molecules that “turn off inflammation.”
- Olive oil, which he describes as helping block excess omega-6s from the food supply that would otherwise drive inflammation upward.
2) Reduce intestinal permeability (“leaky gut”)
In the video, he emphasizes that addressing SIBO is central to reducing intestinal permeability. He states that rifaximin works best in adults, while inulin can go a long way (and he notes children often start with inulin first).
He also discusses cost and access issues with rifaximin in the U.S., describing it as very expensive and noting that some patients obtain it via Canadian mail-order pharmacies.
3) Glutamine for a “secondary form” of leaky gut (as he describes it)
Dr. Nemechek says his practice has been “adding now almost routinely” glutamine to block what he describes as a secondary form of leaky gut into the immune system “being triggered by COVID.” He also states he is recommending that almost everybody start glutamine twice a day and provides an adult amount in the video (one level tablespoon twice a day).
4) Vagus nerve stimulation in some patients
He adds that many patients—especially as they get older—may need vagus nerve stimulation, and he references a “Vagus smart cable” as the method used in his practice.
A clinical observation he shares: blood pressure medications
As an example of what he believes can improve when inflammation is lowered, Dr. Nemechek states that for hypertension he “routinely” gets people off two or three blood pressure medicines, usually within the course of a year. This is presented as his clinical experience within his protocol framework rather than a generalized guarantee for all patients.
Practical takeaway from the video
Dr. Nemechek’s core message is that if SIBO-related inflammatory stress is contributing to chronic illness risk across many disease categories, then addressing SIBO and lowering overall inflammation becomes a personal health priority—not something to wait on until a “magic test” or single drug solution appears. He encourages viewers to review the paper he references, print the chart, and use it to understand the breadth of conditions being discussed in connection with SIBO.
Educational medical disclaimer: This article summarizes a single video and reflects Dr. Patrick Nemechek’s clinical framework and interpretations as presented there. It is not medical advice and is not a substitute for individualized care from your clinician. Do not start, stop, or change medications or supplements without consulting a qualified healthcare professional.
